
As a site manager with 4 years of experience in research industry, I bring a proven track record of driving operational excellence, fostering team collaboration, and meeting performance targets. With a strategic mindset and a commitment to delivering exceptional results, I am equipped to lead as a site director, driving growth, optimizing processes, and ensuring unparalleled customer satisfaction.
A phase 3 Randomized Stratified observer blind placebo controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1273 Sars-COV-2 vaccine in adults aged 18 and older- Lead CRC 2020-present
A randomized double-blind placebo controlled phase 3 efficacy study of an Ad26.RSV.preF based vaccine in the prevention of lower respiratory tract disease caused by RSV in adults age 60 years and older-Lead CRC 2021-present
A phase 3 safety, immunogenicity, and lot consistency trial of the VLP-based Chikungunya vaccine PXVX0317 and healthy adults and adolescence - Lead CRC 2021-present
Phase 3, Multi Center, randomized, double-blind group sequential, placebo controlled study to assess efficacy and safety of rimegepant for the treatment of migraines (with or without aura) in children and adolescents 6 to 18 years old. Lead CRC 2021-present
A phase 3 randomized observer blinded placebo control studies evaluate efficacy safety and immunogenicity of Sars-Cov-2 recombinant spike protein nanoparticle vaccine (SARS-Cov-2 rS) with Matrix-MI adjuvant in adult participants over the age of 18 years old with a pediatric expansion and adolescence 12 to 18 years of age. CO-Lead 2021-present
A second multi center double blind randomize Placebo controlled face retry evaluating the efficacy and safety of Cytisinicline in adult smokers. CO-Lead 2022-present
An Open-label multicenter extension study to characterize a long-term safety and efficacy of BMS-986165 and subjects with modern to severe plaque psoriasis. Lead CRC 2020-present
Phase 1 double blind randomize crossover study and older healthy subject to compare the safety tolerability and pharmacokinetics of LYT -100 (Deupirfenidone) to Pirfenidone CO-Lead 2021.
A phase 1 study to assess the pharmacokinetics of different multiple dose regimens of CT1812 and older healthy volunteers CO-Lead 2022-present
FEMA Certificate IS-00100C
FEMA Certificate IS-00700B
FEMA Certificate IS-00200B
FEMA Certificate IS-00800C